A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.

Also called NCT01643330

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 250 participants (enrolled count) (from the registry)
Sponsor
Celladon Corporation (from the registry)
Registry
  • NCT NCT01643330
  • EudraCT 2012-001700-37
Main results
  • Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial Lancet (London, England), 2016-03-19 DOI, PubMed 26803443

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Belgium, Denmark, Germany, Hungary, Israel, Netherlands, Poland, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01643330. Randomized; quadruple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2015-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
Acronym
CUPID-2b
Condition
Ischemic Cardiomyopathy
Condition
Non-ischemic Cardiomyopathy
Condition
Heart Failure
Condition
Cardiomyopathies
Intervention (Genetic)
AAV1/SERCA2a (MYDICAR)
Intervention (Genetic)
Placebo
Lead sponsor
Celladon Corporation (class: industry)

Record details

Record id
cardio:ct-nct01643330
Content hash
e0aa41624e727bfa1cfc123030926bdc70aaee9e924a92799845f4822da3a6be